felzartamab 
GtoPdb Ligand ID: 13455
|
Synonyms: MOR-03087 | MOR-202 | MOR03087 | MOR202
Compound class:
Antibody
Comment: Felzartamab (MOR03087; MOR202) is a humanized anti-CD38 monoclonal antibody. It has immunosuppressive action and induces Fc-effector function. Anti-CD38 monoclonals are intended to target long-lived CD38+ autoantibody-secreting plasma cells and plasmablasts that persist in inflamed tissue and bone marrow niches, to mediate immunosuppression.
|
| No information available. |
Summary of Clinical Use  |
| Felzartamab (MOR03087) is a clinical candidate that is under evaluation for efficacy in the treament of relapsed/refractory multiple myeloma, renal autoimmune diseases, and for the management of antibody-mediated renal allograft rejection. FDA Breakthrough Therapy Designation was granted (late 2023) for the treatment of primary membranous nephropathy. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01421186 | A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma | Phase 1/Phase 2 Interventional | MorphoSys AG | ||
| NCT05021484 | Felzartamab in Late Antibody-Mediated Rejection | Phase 2 Interventional | Medical University of Vienna | 2-3 | |
| NCT04893096 | MOR202 for Refractory MN | Phase 2 Interventional | Mario Negri Institute for Pharmacological Research | 1-3 | |
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License